biostudies-literatureUnknown9Gao F<h4>Objective</h4>Transarterial chemoembolization with CalliSpheres® Microspheres (CSM-TACE) presents favorable efficacy and tolerable safety in several cancers, while its application in head and neck cancer (HNC) is unclear. Thus, the current pilot study aims to evaluate the efficacy and safety of CSM-TACE in treating HNC.<h4>Methods</h4>A total of 15 HNC patients receiving CSM-TACE at the Second Affiliated Hospital of Dalian Medical University from March 2017 to December 2021 were enrolled in this study. Moreover, treatment information, treatment response, progression-free survival (PFS), overall survival (OS), changes in liver and renal function indices, and adverse events were recorded.<h4>Results</h4>There were nine patients receiving CSM-TACE as first-line treatment and six patients Frontiers in surgery938305https://www.ebi.ac.uk/biostudies/studies/S-EPMC9452835biostudies-literatureEfficacy and safety of transarterial chemoembolization with CalliSpheres® Microspheres in head and neck cancer.PMC9452835Song LGao JGao FWang KfalseEfficacy and safety of transarterial chemoembolization with CalliSpheres® Microspheres in head and neck cancer.<h4>Objective</h4>Transarterial chemoembolization with CalliSpheres® Microspheres (CSM-TACE) presents favorable efficacy and tolerable safety in several cancers, while its application in head and neck cancer (HNC) is unclear. Thus, the current pilot study aims to evaluate the efficacy and safety of CSM-TACE in treating HNC.<h4>Methods</h4>A total of 15 HNC patients receiving CSM-TACE at the Second Affiliated Hospital of Dalian Medical University from March 2017 to December 2021 were enrolled in this study. Moreover, treatment information, treatment response, progression-free survival (PFS), overall survival (OS), changes in liver and renal function indices, and adverse events were recorded.<h4>Results</h4>There were nine patients receiving CSM-TACE as first-line treatment and six patients 2022-01-01T00:00:00Z20222025-04-18T22:43:06.725Z2025-04-07T10:31:42.877ZS-EPMC94528353609031810.3389/fsurg.2022.938305